JPMorgan Reiterates Overweight Rating on Abbvie (ABBV)

July 10, 2025 6:51 AM EDT Send to a Friend
JPMorgan analyst Chris Schott reiterated an Overweight rating and $200.00 price target on Abbvie (NYSE: ABBV)The analyst comments "Ahead of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login